NASDAQ:OBIO Orchestra BioMed (OBIO) Stock Price, News & Analysis $2.88 +0.11 (+3.97%) Closing price 04:00 PM EasternExtended Trading$2.89 +0.01 (+0.35%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Orchestra BioMed Stock (NASDAQ:OBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Orchestra BioMed alerts:Sign Up Key Stats Today's Range$2.79▼$2.9250-Day Range$2.42▼$3.3852-Week Range$2.37▼$8.87Volume116,079 shsAverage Volume186,125 shsMarket Capitalization$110.33 millionP/E RatioN/ADividend YieldN/APrice Target$14.20Consensus RatingBuy Company Overview Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania. Read More Orchestra BioMed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreOBIO MarketRank™: Orchestra BioMed scored higher than 60% of companies evaluated by MarketBeat, and ranked 434th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingOrchestra BioMed has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOrchestra BioMed has only been the subject of 4 research reports in the past 90 days.Read more about Orchestra BioMed's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Orchestra BioMed are expected to decrease in the coming year, from ($1.66) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Orchestra BioMed is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orchestra BioMed is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrchestra BioMed has a P/B Ratio of 3.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.96% of the float of Orchestra BioMed has been sold short.Short Interest Ratio / Days to CoverOrchestra BioMed has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Orchestra BioMed has recently decreased by 12.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOrchestra BioMed does not currently pay a dividend.Dividend GrowthOrchestra BioMed does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.96% of the float of Orchestra BioMed has been sold short.Short Interest Ratio / Days to CoverOrchestra BioMed has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Orchestra BioMed has recently decreased by 12.40%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News Sentiment0.11 News SentimentOrchestra BioMed has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Orchestra BioMed this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Orchestra BioMed to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Orchestra BioMed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,183.00 in company stock.Percentage Held by InsidersOnly 8.10% of the stock of Orchestra BioMed is held by insiders.Percentage Held by Institutions53.55% of the stock of Orchestra BioMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Orchestra BioMed's insider trading history. Receive OBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orchestra BioMed and its competitors with MarketBeat's FREE daily newsletter. Email Address OBIO Stock News HeadlinesHedge funds owners may take dramatic actions as Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) recent 14% drop adds to one-year lossesJuly 2 at 11:39 AM | finance.yahoo.comOrchestra BioMed Confirms Director Elections and AuditorJune 24, 2025 | tipranks.comDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profitable miners selling at deep discounts. I call this price gap the Golden Anomaly — and I’ve put together a full report on my top four picks. July 2 at 2:00 AM | Golden Portfolio (Ad)Orchestra BioMed Highlights Potential of AVIM Therapy for Managing Hypertension in High-Risk Patients at CSI 2025 MeetingJune 20, 2025 | nasdaq.comOrchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 MeetingJune 18, 2025 | msn.comOrchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025June 18, 2025 | globenewswire.comOrchestra BioMed: Two Best-In-Class Devices And Promising PartnershipsMay 28, 2025 | seekingalpha.comOrchestra BioMed Holdings - Breakthrough Device Designation Gives Speculative OptimismMay 14, 2025 | seekingalpha.comSee More Headlines OBIO Stock Analysis - Frequently Asked Questions How have OBIO shares performed this year? Orchestra BioMed's stock was trading at $4.00 at the beginning of the year. Since then, OBIO shares have decreased by 28.0% and is now trading at $2.88. View the best growth stocks for 2025 here. How were Orchestra BioMed's earnings last quarter? Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) announced its earnings results on Monday, May, 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by $0.03. The firm had revenue of $0.87 million for the quarter, compared to analysts' expectations of $0.39 million. Orchestra BioMed had a negative trailing twelve-month return on equity of 189.26% and a negative net margin of 2,297.85%. How do I buy shares of Orchestra BioMed? Shares of OBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Orchestra BioMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Orchestra BioMed investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings5/12/2025Today7/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMedical Equipment Current SymbolNASDAQ:OBIO CIK1814114 Weborchestrabiomed.com Phone646-597-6980FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$14.20 High Stock Price Target$20.00 Low Stock Price Target$12.00 Potential Upside/Downside+393.1%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$61.02 million Net Margins-2,297.85% Pretax Margin-2,297.85% Return on Equity-189.26% Return on Assets-93.76% Debt Debt-to-Equity Ratio0.85 Current Ratio3.35 Quick Ratio3.34 Sales & Book Value Annual Sales$2.64 million Price / Sales41.79 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book3.31Miscellaneous Outstanding Shares38,310,000Free Float35,210,000Market Cap$110.33 million OptionableNot Optionable Beta0.61 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:OBIO) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchestra BioMed Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orchestra BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.